Generic Mepron Availability
MEPRON (atovaquone - suspension; oral)
Has a generic version of Mepron been approved?
No. There is currently no therapeutically equivalent version of Mepron available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mepron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Atovaquone pharmaceutical compositions
Issued: November 18, 2003
Inventor(s): Alan Roy; Dearn
Assignee(s): SmithKline Beecham Corporation
The invention relates to a process for the production of microfluidized particles of atovaquone having improved bioavailability.Patent expiration dates:
- July 10, 2016✓✓✓
- January 10, 2017✓
- July 10, 2016
- Mepron Consumer Information (Wolters Kluwer)
- Mepron Consumer Information (Cerner Multum)
- Mepron Advanced Consumer Information (Micromedex)
- Mepron AHFS DI Monographs (ASHP)
- Atovaquone Consumer Information (Wolters Kluwer)
- Atovaquone Consumer Information (Cerner Multum)
- Atovaquone Advanced Consumer Information (Micromedex)
- Atovaquone AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|